反应详情

To a stirred solution of 2-(6-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (100 mg, 0.34 mmol), EDCI (130 mg, 0.68 mmol), DMAP (83 mg, 0.68 mmol) and DIEA (88 mg, 0.68 mmol) in 6 mL of DMF was added 2-cyclopropylpropan-2-amine hydrochloride (92 mg, 0.68 mmol) in one portion at room temperature, then the mixture was stirred for 16 hours. The reaction mixture was poured into 40 mL of water, filtered and the filter cake was purified by preparative-HPLC (Gemini 5u C18 150×21.2 mm; inject volume: 3 mL/inj, flow rate: 20 mL/min; wavelength: 214 nm and 254 nm; the gradient conditions were: 45% acetonitrile/55% water (0.1% trifluoroacetic acid, v/v) initially, proceeding to 75% acetonitrile/25% water (0.1% trifluoroacetic acid, v/v) in a linear fashion over 9 min.) to give N-(2-cyclopropylpropan-2-yl)-2-(6-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxamide (12 mg, 9.4%) as a yellow solid. MS: (M+H)+=375; 1H NMR (300 MHz, DMSO): δ 13.38 (s, 1H), 12.80 (s, 1H), 9.16 (s, 1H), 8.41-8.35 (m, 2H), 7.95 (s, 1H), 7.41 (s, 1H), 7.06 (d, 1H, J=8.4 Hz), 2.57 (s, 3H), 1.67-1.54 (m, 1H), 1.59 (s, 6H), 0.48-0.44 (m, 4H).

1. filtrationfiltered
2. customthe filter cake was purified by preparative-HPLC (Gemini 5u C18 150×21.2 mm
3. wait45% acetonitrile/55% water (0.1% trifluoroacetic acid, v/v) initially, proceeding to 75% acetonitrile/25% water (0.1% trifluoroacetic acid, v/v) in a linear fashion over 9 min.